If donepezil—a cholinesterase inhibitor used for dementia symptoms—seems unhelpful, the next step is a clinician-led reassessment, not an automatic stop. Depending on the diagnosis and disease stage, options include continuing it, switching drugs, adding or using memantine, and strengthening non-drug care. Ongoing decline does not prove donepezil has failed. It treats symptoms rather than curing Alzheimer's disease, and its effectiveness commonly fades as the disease progresses, according to the National Institute on Aging.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does "not helping" actually mean?
- What should be checked before changing treatment?
- Continue, switch, add memantine, or stop?
- Does the type of dementia change the answer?
- What belongs in the plan beyond medication?
What does "not helping" actually mean?
Donepezil may not produce noticeable improvement. Its benefit may instead appear as slower decline or more stable daily functioning for a period. Families may therefore have difficulty separating medication effects from progression of the disease. Look beyond memory scores when describing the change.
Consider whether the person now needs more help with dressing, meals, medication, communication, safety, or other daily activities. Changes in behavior and caregiver observations also matter. Record what changed, when it changed, and whether the decline was gradual or sudden. This gives the clinician a clearer basis for deciding whether the medicine still offers meaningful benefit.
What should be checked before changing treatment?
A clinician should reconsider the diagnosis, current abilities, medication adherence, side effects, and the full medicine list. The National Institute on Aging's assessment guidance notes that worsening cognition can have causes besides dementia progression.
Possible contributors include: Bring medication bottles or an accurate list to the appointment. Also report missed doses, recent illnesses, new medicines, and changes noticed by someone who knows the person well.
- Delirium or infection
- Medication side effects
- Metabolic or endocrine illness
- Depression
- Vitamin deficiency
Continue, switch, add memantine, or stop?
For mild-to-moderate Alzheimer's disease, switching to rivastigmine or galantamine may make sense when tolerability, adherence, interactions, or another health condition is a concern. However, these cholinesterase inhibitors work similarly, so switching may not produce a substantially better cognitive response. For moderate Alzheimer's, NICE says clinicians should consider adding memantine to an existing cholinesterase inhibitor. For severe Alzheimer's, it recommends offering the combination. Memantine alone is an option when cholinesterase inhibitors are unsuitable, as detailed in the NICE dementia recommendations.
Expect modest, variable effects. In a 295-person randomized trial of moderate-to-severe Alzheimer's, continuing donepezil rather than stopping produced an average 1.9-point cognitive advantage and 3.0 points less impairment in daily activities over 52 weeks. Memantine produced smaller benefits, while combining it with donepezil was not significantly better than donepezil alone in the 2012 New England Journal of Medicine trial. NICE advises regular review of cognition, daily function, behavior, and caregiver observations. It also says not to stop a cholinesterase inhibitor solely because Alzheimer's disease has become severe. Ask the clinician what benefit is still plausible and which observable changes will guide the next review.
Does the type of dementia change the answer?
Yes. Donepezil alternatives are not interchangeable across every dementia diagnosis, so confirming the likely cause matters before selecting another medicine. Rivastigmine is FDA-approved for cognitive symptoms in Parkinson's disease dementia.
For vascular dementia, NICE limits cholinesterase inhibitors or memantine to people with suspected coexisting Alzheimer's disease, Parkinson's disease dementia, or Lewy body dementia. A poor response may therefore prompt a diagnostic review rather than a simple drug substitution. The clinician should consider the pattern of symptoms, functional changes, other illnesses, and previous assessment findings.
What belongs in the plan beyond medication?
Medication is only one part of dementia care. NICE recommends cognitive stimulation therapy as a non-drug intervention for people with mild-to-moderate dementia, including when medication benefit is limited.
Lecanemab is not a general next step for established moderate or severe dementia. FDA labeling limits its initiation to amyloid-confirmed mild cognitive impairment or mild Alzheimer's dementia and requires baseline and repeated MRI monitoring because of the risk of amyloid-related brain swelling or bleeding.
